Viewing Study NCT00528333

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:47 AM
Ignite Modification Date: 2026-03-09 @ 9:20 AM
Study NCT ID: NCT00528333
Status: COMPLETED
Last Update Posted: 2015-01-07
First Post: 2007-09-10
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
Sponsor: Seagen Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Lintuzumab View
None Antigens, CD33 View
None Antibodies, Monoclonal View
None Leukemia, Myeloid, Acute View
None Hematologic Diseases View
None Leukemia View